The role of pelvic lymphadenectomy (LA) in women with stage I endometrial carcinoma (EC) is controversial. The objective of this study is to investigate the prognostic impact of LA on survival endpoints in matched cohorts of women with stage I EC solely of endometrioid histology. Survival endpoints included recurrence-free (RFS), disease-specific (DSS) and overall survival (OS).
Methods and materials
Patients with FIGO stage I EC who underwent hysterectomy with LA as part of their surgical staging between 1/1990 and 6/2015 were matched to a similar group that underwent hysterectomy without lymphadenectomy (NLA), based on stage, grade and adjuvant management. Univariate and multivariate modeling with Cox regression analysis was carried out for predictors of survival endpoints.
870 women constituted the study cohort (435 in each group). Median number of dissected lymph node in the LA group was 9 (range, 5–75). There was no statistically significant difference between the two groups in regards to 5-year OS (87.2% for LA vs. 91.7% for NLA) (p = 0.36), DSS 97.7% vs. 98% (p = 0.54) and RFS (93.7% vs. 90% (p = 0.08), respectively. Lymphadenectomy was not a predictor of any of the studied survival endpoints. On multivariate analysis for the entire cohort, older age, deep myometrial invasion and higher tumor grade were predictors of worse RFS. For DSS, higher tumor grade, lower uterine segment (LUS) involvement and FIGO stage IB were significant predictors of worse outcome. For OS, older age and LUS involvement were the only two independent predictors for shorter OS.
After matching for FIGO stage, grade and adjuvant management, it appears that lymphadenectomy in women with stage I EC does not impact survival endpoints.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer statistics.CA Cancer J Clin. 2015; 65: 5-29
- Carcinoma of the corpus uteri: FIGO annual report.Int J Gynecol Oncol. 2006; 26: S105-43
- Heller PB.Surgical pathologic spread patterns of endometrial cancer. a gynecologic oncology group study.Cancer. 1987; 60: 2035-2041
- Nodal metastasis risk in endometrioid endometrial Cancer.Obstet Gynecol. 2012; 119: 286-292
- Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging.J Natl Compr Canc Netw. 2014; 12: 288-297
- Sentinel node biopsy in endometrial cancer: systematic review and meta-analysis of the literature.Eur J Gynaecol Oncol. 2013; 34: 387-401
ACOG Practice Bulletin. Clinical management guidelines for obstetrician–gynecologists, number 149, Endometrial cancer. Obstet Gynecol 2015; 125 (4): 1006–1026.
- Parmar MK.Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study.Lancet. 2009; 373: 125-136
- Systematic pelvic lymphadenectomy vs: no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.J Natl Cancer Inst. 2008; 100: 1707-1716
- Omission of lymphadenectomy is possible for low-risk corpus cancer.Euro J Cancer Surg. 2007; 33: 86-90
- The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma.Gynecol Oncol. 2009; 112: 511-516
- Can a lymphadenectomy be avoided in early-stage endometrial adenocarcinoma?.Arch Gynecol Obstet. 2014; 290: 973-978
- Should all endometrioid uterine cancer patients undergo systemic lymphadenectomy?.Eur J Surg Oncol. 2013; 39: 344-349
- Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling.Gynecol Oncol. 1995; 56: 29-33
- Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?.BMC Cancer. 2010; 10: 224
- The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer.Int. J. Radiat Oncol Biol Phys. 2012; 82: 1872-1879
- Lymph node sampling and survival in endometrial cancer.Gynecol Oncol. 1998; 71: 340-343
- Role of systematic lymphadenectomy and adjuvant radiation in early-stage endometrioid uterine cancer.Ann Surg Oncol. 2010; 17: 2951-2957
- Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.Gynecol Oncol. 2006; 102: 92-97
- Impact of lymphadenectomy in uterine endometrioid carcinoma.Eur J Surg Oncol. 2013; 39: 350-357
- Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis.Jpn J Clin Oncol. 2012; 42: 405-412
- Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.J Clin Oncol. 2005; 23: 3668-3675
- The outcomes of 27,063 women with unstaged endometrioid uterine cancer.Gynecol Oncol. 2007; 106: 282-288
- The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.N Engl J Med. 1985; 312: 1604-1608
- The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis.Am J Obstet Gynecol. 2012; 206 (e1–500. e11): 500
- Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial carcinoma.Int J Radiat Oncol Biol Phys. 2014; 88: 351-356
- A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2004; 92: 744-751
- Surgery and postoperative radiotherapy versus surgery alone for patients with stage I endometrial carcinoma: multicentre randomized trial-PORTEC Study Group, Post Operative Radiation Therapy in Endometrial Carcinoma.Lancet. 2000; 355: 1404-1411
- Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.Gynecol Oncol. 2008; 109: 11-18
- ESMO-ESGO-ESTRO consensus conference on endometrial cancer; diagnosis, treatment and follow-up.Int J Gynecol Cancer. 2016; 26: 2-30
- Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life.Obstet Gynecol. 2014; 124: 307-315
- Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research.Gynecol Oncol. 2015; 138: 478-485
- Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer.Gynecol Oncol. 2013; 131: 593-597
- Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer.Arch Gynecol Obstet. 2015; 292: 1321-1327
- Lymphadenectomy for the management of endometrial cancer.Cochrane Database of Syst Rev. 2015; 9: CD007585
- Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy.Eur J Obstet Gynecol Reprod Biol. 2013; 170 (Epub 2013 Aug 7): 539-543https://doi.org/10.1016/j.ejogrb.2013.07.037
Published online: December 28, 2016
Accepted: December 25, 2016
Received in revised form: December 21, 2016
Received: November 15, 2016
© 2016 Elsevier Ireland Ltd. All rights reserved.